GlassScriptPhysician profile
Doris V Pablo -Bustos
NPI 1275635559
$8,566.10
in general payments reported to CMS, 2019-2025
44 companies · $1,105 in 2025
The $1,105 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,021 · 2020: $1,263 · 2021: $1,939 · 2022: $1,314 · 2023: $622 · 2024: $1,302 · 2025: $1,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,029.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,499.73 | 2019-2025 | Farxiga, Lokelma, Airsupra |
| Lilly USA, LLC | $1,067.58 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $872.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $409.79 | 2019-2025 | Jardiance |
| Pfizer INC. | $334.23 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $292.34 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $232.15 | 2019-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $229.16 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $226.09 | 2020-2025 | Zoryve |
| Amgen INC. | $217.90 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $194.60 | 2020-2022 | |
| Akebia Therapeutics INC | $167.88 | 2020-2023 | Auryxia |
| Mallinckrodt Hospital Products INC. | $137.38 | 2020-2022 | |
| Medtronic, INC. | $134.90 | 2022-2024 | Symplicity G3 |
| Vifor Pharma, INC. | $131.26 | 2019-2025 | Veltassa |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doris Pablo -Bustos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.